This content is PDF only. Please click on the PDF icon to access.
Abstract
Transcorneal permeation has traditionally been the mechanism by which topically applied ophthalmic drugs are believed to gain access to the internal ocular structures. Relatively little attention has been given to alternate routes by which drugs may enter the eye. A system has been developed which allowed the investigation in vivo of the contribution of noncorneal absorption to intraocular drug levels after topical dosing. Using timolol and inulin as probe drugs, it was shown that the noncorneal absorption route may contribute significantly to drug penetration into intraocular tissues. Furthermore, results demonstrated that drugs absorbed by the noncorneal route appeared to enter certain intraocular tissues by a mechanism which bypasses the anterior chamber. These studies suggested that intraocular penetration via noncorneal routes involves penetration of drug across the conjunctiva/sclera. Neither reentry from the general circulation after drug absorption into the blood or drug delivery by the local vasculature accounted for the observed results. In terms of topical ophthalmic drug delivery, the noncorneal absorption route may be important for drugs that are poorly absorbed across the cornea due to their physical-chemical properties. We have demonstrated this using inulin as a model for a poorly absorbed, high molecular weight substance.